CagriSema
Also known as: Cagrilintide + Semaglutide · Cagri/Sema
An investigational fixed combination of the amylin analog cagrilintide with the GLP-1 agonist semaglutide.
CagriSema at a glance
| Name | CagriSema |
|---|---|
| Also known as | Cagrilintide + Semaglutide, Cagri/Sema |
| Category | Metabolic & weight |
| Type | Peptide |
| Sequence | Blend — not a single peptide (cagrilintide + semaglutide). |
| Typical dose | Trial dosing titrates upward; specific figures are protocol-dependent |
| Frequency | Once weekly in studied regimens |
| Route | Subcutaneous injection, typically once weekly (trials) |
| Half-life | Both components are long-acting (on the order of days). |
Overview
CagriSema pairs cagrilintide (a long-acting amylin analog) with semaglutide (a GLP-1 receptor agonist), two appetite-regulating pathways in one weekly injection. It has been studied in clinical trials for weight management, but the combination is investigational and not an approved product; research-market versions are unregulated. Nothing here is a recommendation to use it.
How it’s thought to work
- Semaglutide activates GLP-1 receptors to increase satiety and slow gastric emptying.
- Cagrilintide mimics amylin, which also reduces appetite and food intake.
- The two are combined to act on complementary appetite pathways.
Researched uses
- Investigational weight management in trials
- Appetite and blood-sugar regulation research
Commonly cited protocol
| Typical dose | Trial dosing titrates upward; specific figures are protocol-dependent |
|---|---|
| Frequency | Once weekly in studied regimens |
| Route | Subcutaneous injection, typically once weekly (trials) |
| Notes | Investigational combination; not an established or approved regimen. |
Reconstitution
Research versions ship as a combined lyophilized vial. Use the blend calculator to find units per component after reconstitution.
Cautions
- Investigational combination; not FDA-approved.
- GLP-1/amylin agonists commonly cause nausea and GI effects.
- Unregulated research versions vary in content and purity.
CagriSema FAQ
What is CagriSema?
An investigational fixed combination of the amylin analog cagrilintide with the GLP-1 agonist semaglutide.
How does CagriSema work?
Semaglutide activates GLP-1 receptors to increase satiety and slow gastric emptying. Cagrilintide mimics amylin, which also reduces appetite and food intake. The two are combined to act on complementary appetite pathways.
What is CagriSema used for?
Investigational weight management in trials; Appetite and blood-sugar regulation research.
What is a typical CagriSema dose?
Trial dosing titrates upward; specific figures are protocol-dependent, Once weekly in studied regimens, Subcutaneous injection, typically once weekly (trials). This is a commonly cited figure for context only, not medical advice.
How do you reconstitute CagriSema?
Research versions ship as a combined lyophilized vial. Use the blend calculator to find units per component after reconstitution.
What is the half-life of CagriSema?
Both components are long-acting (on the order of days).